Heather Kaiser, a 43-year-old attorney and mother of two young boys, was diagnosed with early-onset colon cancer at 42. Her story is one of persistence, rapid scientific advances and a deliberate choice to keep living a full life while managing a chronic, serious illness.
At first, Heather’s gastrointestinal symptoms were dismissed as hormonal or dietary. After a return visit to the emergency room and ongoing symptoms, a follow-up with her OB-GYN led to a referral for a colonoscopy. Physicians found a mass described as roughly the size of a fist. Pathology confirmed colon cancer. Heather took a day to absorb the news before telling her family and arranging surgery for June 2025, timed so she could be present for her sons’ school year.
The operation proceeded as planned, but surgeons worried the margins might not be clear. Her tumor was sent for molecular testing, and while she waited for results she had a PET scan that revealed metastatic disease—spread to lymph nodes near the lungs and to the liver, an atypical pattern. Biomarker testing identified a BRAF V600E mutation, a change seen in roughly 10% of metastatic colorectal cancers and often linked with a poorer prognosis. At the time, doctors estimated a prognosis of about 13 months.
Because targeted options were becoming available for BRAF V600E tumors, Heather enrolled in a protocol in August 2025 tied to the BREAKWATER research effort. She became the first person in Minnesota to receive that protocol outside the original trial, jokingly calling herself ‘Patient Zero.’ Her regimen combined four drugs—three given intravenously and one oral targeted agent, Braftovi. Prior to Braftovi-based combinations, cancers with her mutation were frequently resistant to standard chemotherapy; Braftovi is designed to block pathways that help cancer cells grow and can enhance the effects of other drugs.
Treatment was effective but not without side effects. Heather experienced increased sensitivity to cold and persistent nausea that resisted many conventional anti-nausea medicines. She found symptom relief using an oral cannabis pill at night and a CBD gummy in the morning to help with nausea and fatigue. After eight treatment cycles, a CT scan in October 2025 showed a complete response: no evidence of disease on imaging. The speed and depth of that response surprised her care team, who noted that such rapid complete responses were uncommon even in trial settings.
Despite that encouraging scan, Heather continues on therapy. The BRAF V600E subtype is generally considered incurable with current treatments and often requires continuous therapy to keep the cancer controlled. Her clinicians emphasized that durable, treatment-free remissions remain rare for this mutation; ongoing treatment is intended to suppress disease over time.
Heather balances full-time work with family life and ongoing treatment. Fatigue and reduced stamina are constant challenges, but a strong network of family, friends and neighbors supports her ability to keep working and care for her sons. She credits regular exercise, which she maintained through treatment, for helping her stamina and outlook. Her mindset has been to plan life first and ‘fit cancer in there’—not to let the disease dictate every decision.
Her experience highlights several lessons: persist when symptoms don’t feel right, advocate for thorough evaluation, and insist on molecular testing to guide therapy options. It also illustrates how targeted clinical trials can offer meaningful benefit in situations that previously had limited options. Heather continues to work with the legal team at RVO Health, Healthline’s parent company, and to live intentionally with her family while navigating an indefinite treatment plan.